MADISON, Wis. and PHOENIX, March 3, 2020 /PRNewswire/ -- (NASDAQ: EXAS) – Exact Sciences Corp. today announced the completion of its acquisitions of Paradigm Diagnostics, Inc. and Viomics, Inc., two ...
MADISON, Wis. - Exact Sciences Corp. (NASDAQ: NASDAQ:EXAS), a prominent cancer screening and diagnostics company, announced today that the U.S. Food and Drug Administration (FDA) has approved the ...
Exact Sciences Corp. (NASDAQ: EXAS) is on a self-proclaimed mission to change the way cancer is detected and treated. The Madison, Wisconsin company is among the market’s best price performers, ...
This article updates the investment merits of Exact Sciences following its disappointing Q3, 2024 earnings. Recent approval of an improved version of its lead product will not show up in revenues for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results